AnaptysBio has separately alleged that GSK subsidiary Tesaro breached “certain requirements” under their 2014 license agreement involving a program that would become GSK’s Jemperli.
AnaptysBio has separately alleged that GSK subsidiary Tesaro breached “certain requirements” under their 2014 license agreement involving a program that would become GSK’s Jemperli.